Physician profile
Jayakumar Patil
NPI 1144339417
$7,768.36
in general payments reported to CMS, 2019-2025
24 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,133 · 2020: $208 · 2021: $756 · 2022: $676 · 2023: $999 · 2024: $798 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,285.35 | 2019-2025 | Spravato |
| Abbvie INC. | $775.94 | 2022-2025 | |
| Allergan, INC. | $673.38 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $629.29 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $620.62 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $589.57 | 2019-2021 | |
| Lundbeck LLC | $539.41 | 2019-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $488.55 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $367.98 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $364.49 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $228.08 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $216.12 | 2019 | |
| Corium, LLC | $190.40 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $161.26 | 2025 | Fanapt |
| Shire North American Group INC | $157.82 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $104.89 | 2022-2025 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $61.02 | 2019 | |
| Pfizer INC. | $56.68 | 2019 | |
| Biogen, INC. | $54.84 | 2023-2025 | Zurzuvae |
| Neos Therapeutics, Lp | $35.96 | 2019 | |
| Neurocrine Biosciences, INC. | $32.35 | 2019 | |
| Alfasigma USA, INC. | $19.97 | 2022 | |
| Noven Therapeutics, LLC | $15.93 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayakumar Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.